Centrum Medyczne Neuroprotect

Warsaw 43 trials 17 recruiting

43 Registered trials

17 Currently recruiting

Organisation

Centrum Medyczne Neuroprotect

Location

Warsaw, Poland

Identifier

ORG-100043452

Address

Ul. Klaudyny 16c, 1 Piętro, 01-684, Poland

Departments

-
#40536: N/A
301-103: Centrum Medyczne Neuroprotect
Centrum Medyczne NeuroProtect
Centrum Meyczne Neuroprotect
N/A
NA
NA/ND
Neurology

Clinical trials at this site (43)

Search interface

Comparative PK, PD, efficacy, safety and immunogenicity assessment of the proposed ocrelizumab biosimilar CYB704 and Ocrevus in participants… Ended

2024-512319-40-00 Subjects with relapsing multiple sclerosis (relapsing r 5 2025-07-01
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended

2022-501644-15-01 Mild Cognitive Impairment due to Alzheimer's Disease Al 4 2023-09-28
A study into the efficacy and safety of dazucorilant (CORT113176) in patients with Amyotrophic Lateral Sclerosis Ended

2024-514082-19-00 Amyotrophic Lateral Sclerosis 4 2022-11-04
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS) Ended

2023-505641-12-00 Amyotrophic Lateral Sclerosis (ALS) associated with SOD 5 2021-07-27
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended

2023-507132-21-00 Early Parkinson's disease 10 2021-05-11
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended

2022-502611-10-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-11-24
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended

2023-506515-18-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-10-23
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended

2023-506467-34-00 Relapsing Multiple Sclerosis (MS) 5 2020-10-20
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended

2023-505980-36-00 Primary progressive multiple sclerosis (PPMS) 5 2019-09-19
A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended

2023-508821-28-00 Migraine 4 2024-08-14
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult… Ended

2022-502552-31-00 Relapsing Forms of Multiple Sclerosis 4 2023-10-03
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effe… Ended

2023-510317-26-00 Amyotrophic Lateral Sclerosis 4 2023-02-07
Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasth… Ended

2024-512258-91-00 Generalized Myasthenia Gravis (gMG) 5 2023-02-03
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis… Ended

2022-500424-30-00 Parkinson’s disease 4 2022-12-28
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended

2023-505645-12-00 Parkinson's Disease 4 2022-11-28
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the S… Ended

2024-511610-20-00 Alzheimer's Disease 4 2022-11-08
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended

2023-506918-45-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended

2023-506919-18-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended

2023-507303-55-00 Alzheimer Disease 4 2020-09-30